French biopharmaceutical Osivax, which is developing vaccines to provide broad-spectrum protection against highly mutating ...

Osivax secures strategic funding to accelerate the development of its influenza vaccine candidates: Lyon, France Wednesday, March 5, 2025, 16:00 Hrs [IST] Osivax, a biopharmaceuti ...

Meiji Seika Pharma Co. said on Dec. 25 it is seeking 10 million yen ($63,500) in damages from Kazuhiro Haraguchi, a Lower House member of the main opposition Constitutional Democratic Party of Japan.

The firm's endorsement follows the announcement that Meiji Seika Pharma, a division of Meiji Holdings trading on the Tokyo Stock Exchange under ticker 2269, has been granted approval for a key ...

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...

gave the green light to CSL and Arcturus’ COVID-19 vaccine ARCT-154 – also known as Lunar-COV19 – which will be commercialised in Japan by partner Meiji Seika Pharma. Japan is the first ...

TOKYO, January 31, 2025--(BUSINESS WIRE)--Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi) announced today that it has received ...

Reports Q4 revenue $22.8M, consensus $44.64M. “We continue to progress our flagship rare disease programs and look forward to sharing ...

The company is pleased to welcome Meiji Seika Pharma Co., Ltd, a leading Japanese pharmaceutical company specializing in infectious diseases, as a new investor. With a legacy spanning over 75 ...

We are very pleased to have recently received European Commission approval for KOSTAIVE® and MHLW approval for Meiji Seika Pharma and ARCALIS to add commercial manufacturing sites in Japan.